Skip to content

Diseases

World Gastrointestinal Disorders Market 2006-2011; The

 

Publication Date January 2006
Publisher Visiongain
Product Type Report
Pages 169
ISBN Number not applicable
Product Code VIS00026

Price

£1,799.00
approximately: $2,756 | €2,005

other

Buy Now

Order above formats by FAX

Order by Fax

Summary

Please Note: Reports are sold based on the user licenses indicated. The reports will be accessible in Flash format via an online reading room on the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the client will receive an email with information on accessing their purchase.

The purpose of this visiongain report is to examine the prospects of the world gastrointestinal market. The gastrointestinal (GI) disorders market is one of the largest and most important in the pharmaceutical industry, generating revenues of over $16 billion in 2004. This report examines the GI market critically through a comprehensive review of available information, including that from commercial databases, consultation with the industry, company reports, business/industry news and consultation with international experts on GI disorders. Visiongain applied techniques such as financial forecasting, SWOT analysis and the assessment of unmet needs to provide a comprehensive market report with detailed analyses and informed opinion.

In particular, this report concentrates on the following essential aspects of the GI market:
  • The current state of the world market for drugs to treat gastrointestinal disorders
  • Drivers and opportunities in the GI market
  • Restraints and threats in the GI market
  • Revenue trends in the world gastrointestinal market between 2005-2011
  • Prospects for the leading GI drugs between 2005-2011
  • A comprehensive discussion of patent expiry and generic substitution
  • An assessment of prescription-to-OTC switching and lifecycle management
  • A breakdown of the world GI market into the principal geographical regions, with estimates of potential treatment populations and forecasted revenues to 2011
  • An analysis of unmet needs in the GI market, with discussion of potential solutions
  • A discussion of pricing, with comparisons between leading products and substitutes
  • A discussion of DTC advertising with emphasis on issues and strategies
  • Detailed information on pipeline products, with an analysis of the prospects for these agents
Why you should buy this report?
  • To receive a comprehensive analysis of the prospects of the world gastrointestinal market from 2005-2011
  • To find out predicted revenues, growth rates and market shares for all the leading GI drugs from 2005-2011
To determine the forces that influence the gastrointestinal market, especially:
  • Competitive characteristics
  • Drivers and restraints
  • Strengths, weaknesses, opportunities and threats
  • Unmet needs according to world experts, with gaps in the market exposed
To find out the prospects for GI drugs in the leading geographical markets:
  • Potential treatment populations
  • Potential 2011 revenues in the leading 7 markets
  • To find out about pipeline developments for treating GI disorders

Contents

  • 1. Executive Summary - Gastrointestinal Treatments Constitute a Large Market
  • 2. Introduction to Gastrointestinal Disorders
    • 2.1 Gastrointestinal Disorders Constitute a Large Market for Pharmacological Treatments
      • 2.1.1 Gastrointestinal Disorders have a Significant Economic Impact on Society
      • 2.1.2 The Market for Gastrointestinal Drugs Generates Large Revenues and is well Represented in the Top 100 Best Selling Prescription Drugs
    • 2.2 Gastroesophageal Reflux Disease
      • 2.2.1 What is Gastroesophageal Reflux Disease (GERD)?
      • 2.2.2 Aetiology of GERD
      • 2.2.3 Symptoms of the Condition
      • 2.2.4 Diagnosis of GERD
      • 2.2.5 Prevalence of GERD
      • 2.2.6 Economic Impact of GERD
      • 2.2.7 Treatment of GERD
    • 2.3 Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)
      • 2.3.1 What is Crohn's Disease?
      • 2.3.2 Aetiology of Crohn's Disease
      • 2.3.3 Symptoms of Crohn's Disease
      • 2.3.4 Diagnosis of the Condition
      • 2.3.5 What is Ulcerative Colitis?
      • 2.3.6 Aetiology of Ulcerative Colitis
      • 2.3.7 Symptoms of Ulcerative Colitis
      • 2.3.8 Diagnosis of Ulcerative Colitis
      • 2.3.9 Worldwide Prevalence of Inflammatory Bowel Disease Crohn's Disease is Becoming Increasingly Prevalent Throughout the World
      • 2.3.10 Economic Burden of Inflammatory Bowel Disease
      • 2.3.11 Treatment of Inflammatory Bowel Disease
    • 2.4 Irritable Bowel Syndrome
      • 2.4.1 Overview of Irritable Bowel Syndrome
      • 2.4.2 Aetiology of Irritable Bowel Syndrome
      • 2.4.3 Symptoms of Irritable Bowel Syndrome
      • 2.4.4 Diagnosis of Irritable Bowel Syndrome
      • 2.4.5 Prevalence of Irritable Bowel Syndrome
      • 2.4.6 The Cost of Irritable Bowel Syndrome
      • 2.4.7 Treatment of Irritable Bowel Syndrome
    • 2.5 Peptic Ulcer Disease
      • 2.5.1 What is Peptic Ulcer Disease?
      • 2.5.2 Aetiology of Peptic Ulcer Disease
      • 2.5.3 Symptoms of the Condition
      • 2.5.4 Diagnosis of Gastric Ulcers
      • 2.5.5 Helicobacter Pylori: often the Putative Causative Agent of Ulcers
      • 2.5.6 Zollinger-Ellison Syndrome - A Rare Disorder that can be Treated by Acid-Suppressing Drugs
      • 2.5.7 Demographic Prevalence of Peptic Ulcers
      • 2.5.8 Economic Impact of Peptic Ulcers
    • 2.6 An Overview of the Gastrointestinal Drug Market
    • 2.7 Histamine H2 Receptor Antagonists for the Treatment of Gastrointestinal Disorders
      • 2.7.1 Histamine H2 Receptor Antagonists: an Older Drug Class that Retains a Market Presence Among the Leading Gastrointestinal Drugs
      • 2.7.2 Modes of Action for Histamine H2 Receptor Antagonists Inhibitors
    • 2.8 Proton Pump Inhibitors for the Treatment of Gastrointestinal Disorders
      • 2.8.1 Proton Pump Inhibitors are a Newer Class of Medication - Currently these Agents Lead the Gastrointestinal Market
      • 2.8.2 The Proton Pump Inhibitors - their Modes of Action
    • 2.9 Other Drugs for Treating Gastrointestinal Disorders
      • 2.9.1 OTC Antacids
      • 2.9.2 Bismuth Subsalicylate
      • 2.9.3 Sucralfate
      • 2.9.4 Prokinetic Agents
      • 2.9.5 Aminosalicylic Acid (5-ASA) Compounds
      • 2.9.6 Mesalamine
      • 2.9.7 Sulfasalazine
      • 2.9.8 Corticosteroids
      • 2.9.9 Remicade (infliximab)
      • 2.9.10 Antibiotics
  • 3. The World Gastrointestinal Market 2004-2011
    • 3.1 Shifting Internal Dynamics Cause a Marked Overall Decline of Revenues in the Prescription Gastrointestinal Market Between 2004-2011
    • 3.2 AstraZeneca to Remain the Leading Company in the 2011 Prescription Gastrointestinal Market
      • 3.2.1 Collaborations in the GI Market
    • 3.3 Proton Pump Inhibitors to Continue their Domination of the Gastrointestinal Market, 2005-2011
    • 3.4 There will Remain Potential for Blockbuster Revenues in the Gastrointestinal Market During 2005-2011
    • 3.5 OTC Switching Creates Good Opportunities for Life Cycle Management - But at what Cost to Prescription Drug Revenues?
    • 3.6 The GI Market is Likely to Remain Strong in Terms of Prescription Numbers and Unit Sales - But Generics will Continue to be a Threat
  • 4. The World Market for Proton Pump Inhibitors, 2005-2011
    • 4.1 The Proton Pump Inhibitors - A Market Under Increasing Threat from Patent Expiry and OTC Switching
    • 4.2 Loss of Patent Protection will have a Significant Effect on Revenue Generation in the PPI Market
      • 4.2.1 OTC Prilosec and Generics will Continue to Play a Decisive Role in the Dynamics of the GI Market
    • 4.3 Market Shares of the Leading GI Drugs - 2005 and 2011 Compared
    • 4.4 Nexium will Face Declining Revenues and Loss of Predominance in the World Gastrointestinal Market
      • 4.4.1 Sales of Nexium Increased Strongly in the First Three Quarters of 2005
      • 4.4.2 Brand Management is Succeeding for AstraZeneca - Will Competitors be able to Emulate this Winning Strategy?
      • 4.4.3 AstraZeneca Commences Litigation Against Ranbaxy Laboratories Regarding Alleged Patent Infringement on Nexium
      • 4.4.4 Recently AstraZeneca Lost an Important Contract to Supply Nexium - Will Nexium Face Other Setbacks like this?
      • 4.4.5 Nexium Receives FDA Approval for Risk Reduction of NSAID-Related Ulcers
      • 4.4.6 Nexium I.V. Approved as a Short-Term Treatment for GERD
      • 4.4.7 The Promotion and Marketing of Nexium Beset by Legal Challenges
    • 4.5 Prevacid - Another Major PPI that Faces Declining Revenues
      • 4.5.1 TAP Pharmaceutical Inc, a Joint Venture Shared Between Abbott and Takeda: Prevacid is its Leading Product
      • 4.5.2 Abbott Admits Increased Competition for Prevacid and Contraction of the PPI Market
      • 4.5.3 TAP Reconsiders Expenditure on DTC Advertising for Prevacid
      • 4.5.4 FDA Extends Approval for Prevacid Delayed Release Orally Disintegrating Tablets
      • 4.5.5 Prevacid Receives Extended Paediatric Approval from FDA
      • 4.5.6 FDA Approves Prevacid I.V. for Erosive Esophagitis in Hospitalised Patients
    • 4.6 Prilosec/Losec - AstraZeneca Uses Product Lifecycle Management Decisively
      • 4.6.1 Prilosec/Losec Revenues Declined Sharply During Q1-Q3 of 2005 - But there was Marked Growth in China and Japan
      • 4.6.2 Generic Substitutes will Increasingly Threaten the Vulnerable Prilosec/Losec Brand
      • 4.6.3 AstraZeneca Facing EU Patent Abuse Charges Concerning Losec
    • 4.7 Protonix is another Leading PPI Facing Patent Expiry later this Decade
      • 4.7.1 Protonix is a Strong Performer with Increasing Revenues from 2002-2005
      • 4.7.2 Protonix Benefited from Early FDA Approval for Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome
    • 4.8 Pantozol will Experience Patent Expiry, Leading to a Sharp Decline in Revenue
      • 4.8.1 Wyeth Acts as a Partner for Sales of Pantoprazole in the US
      • 4.8.2 Patent Protection for Pantoprazole Extended to 2010 in the US; Similar Protection in Europe - Altana Optimistic Over Continuing Revenue Growth
      • 4.8.3 Pantozol Continues to Perform Well in 2005
      • 4.8.4 Sales in Germany Declined Slightly Due to Mandatory Discount - Altana Challenges State's Decision
    • 4.9 Takepron will Supplant Nexium to Become the Leading PPI
      • 4.9.1 Takeda Developed Lansoprazole
      • 4.9.2 Revenues for Takepron During Part of 2005 Revealed Disappointing Growth Rate
    • 4.10 Aciphex/Pariet will Continue to Grow Moderately in Revenue
    • 4.10.1 Eisai's Long-Running Commercial Arrangement with Johnson & Johnson for Aciphex/Pariet
    • 4.10.2 Eisai Commences US Legal Actions Over ANDA Filings for Generic Versions of Aciphex/Pariet
    • 4.10.3 Eisai Receives European Marketing Authorization for PARIET for Zollinger-Ellison Syndrome
    • 4.10.4 Eisai Applies For A New Indication for Pariet in Japan for Eradicating H. Pylori
    • 4.10.5 New Production Facilities for Aciphex/Pariet Incorporate Latest Technology to Achieve Cost Savings
    • 4.11 Zoton's Loss of Patent Protection will Cause this Product Difficulties in the Market
    • 4.11.1 Zoton Displayed Increasing Revenues Until 2004 but Faced a Downturn in 2005
    • 4.11.2 Zoton Released in OTC Form - How well will it Compete with Prilosec OTC and Other Preparations?
    • 4.12 Prevacid/Ogastro
    • 4.13 The Market for Proton Pump
    • 4.13 Inhibitors: Summary and Conclusions
  • 5. The World Market for Histamine H2 Receptor Antagonists and Other Leading Gastrointestinal Drugs, 2004-2011
    • 5.1 Histamine H2 Antagonists - This Older Class will Suffer Declining Revenues from 2005-2011
      • 5.1.1 The H2 Antagonists are Now a Mature Drug Class Characterised by the Loss of Patent Protection and Availability of Generic Substitutes
      • 5.1.2 Both Gaster and Zantac are Available in OTC Formulations
    • 5.2 Gaster - This Older Drug Faces Continuing Decline
      • 5.2.1 Prescription Gaster will Continue to Lose Sales to OTC Formulation (Gaster 10)
      • 5.2.2 Prescription Sales of Gaster in 2005 Show a Decline - Further Decline Predicted
    • 5.3 Zantac - Loss of Patent Protection Accelerates the Decline of this Brand
      • 5.3.1 Zantac is Marketed in Japan by Sankyo Under Licence from GlaxoSmithKline
      • 5.3.2 Sales of Zantac are Declining in All Regions
      • 5.3.3 Zantac EFFER dose Formulation for GERD In Children May Help to Slow Decline
    • 5.4 Other Leading GI Agents will Exhibit Growth in Revenue
    • 5.5 Zelnorm/Zelmac - Will Continue to Perform Strongly
      • 5.5.1 Revenues of Zelnorm/Zelmac will Continue to Increase in 2005
      • 5.5.2 Zelnorm/Zelmac is Currently Being Developed for Other Important GI Indications
    • 5.6 Gasmotin - Steady Growth Leads to Maturity
      • 5.6.1 Dainippon Pharmaceutical is Striving To Maintain Growth of Key Product Gasmotin
      • 5.6.2 Gasmotin Currently Being Developed Further - New Indication Sought
    • 5.7 Nauzelin Will Experience Falling Revenues
    • 5.8 Canasa/Salofalk will Produce Steady Growth for Axcan Pharma
      • 5.8.1 Axcan Pharma is a Specialist Pharmaceutical Company Focused on Gastroenterology
    • 5.9 The Market for H2 Antagonists and Other Leading GI
  • Agents: Summary and Conclusions
    • Abbott Laboratories
    • Adolor Corp
    • Alizyme
    • Altana
    • Andrx Pharma
    • Apotex Corporation
    • Astellas Pharma
    • AstraZeneca
    • Axcan Pharma
    • Bentley Pharmaceuticals
    • Berlex Inc
    • Bristol-Myers Squibb
    • Centocor Inc
    • Consilient Health
    • CyberPharm Investment Co
    • Daewoong Pharmaceutical Co
    • Dainippon Pharmaceutical
    • Dainippon Sumitomo Pharma Co
    • Dr Reddy's Laboratories
    • Eisai
    • Eon Labs Manufacturing
    • General Motors
    • Genpharm Inc
    • Genzyme Corp
    • GlaxoSmithKline
    • Ilyang Pharmaceutical Company
    • Impax Laboratories
    • Ivax Pharmaceuticals
    • Janssen Pharmaceutica
    • Johnson & Johnson
    • KUDCo
    • Kyowa Hakko Kogyo
    • Laboratorios Davur
    • Lek Pharmaceutical and Chemical Company
    • Lek Services USA
    • Merck & Co
    • Merck KGaA
    • Motorola
    • Mylan Pharmaceuticals
    • Novartis
    • NPS Pharmaceuticals
    • Otsuka America Pharmaceutical
    • Pain Therapeutics
    • Par Pharma
    • Pfizer
    • Proctor & Gamble
    • Progenics Pharmaceuticals
    • Ranbaxy Laboratories
    • Roche
    • Salix Pharmaceuticals
    • Sandoz
    • Sankyo
    • Sanofi-Aventis
    • Santarus
    • Schering AG
    • Schwarz Pharma
    • Shire US Inc
    • Solvay Pharmaceuticals
    • Sucampo Pharmaceuticals
    • Sumitomo Pharmaceuticals Co
    • Takeda Chemical Industries
    • Takeda Pharmaceutical
    • TAP Pharmaceutical Products
    • Teva Pharmaceuticals
    • Teva USA
    • Torpharm
    • UCB Pharma
    • Wal-Mart
    • Wyeth
    • Zenith Goldline Pharmaceuticals